75th Anniversary of Glucocorticoids - what have we learnt?

Sytske Anne Bergstra at the recent EULAR 2024 chaired a session on the use of glucocorticoids in the therapy of rheumatoid arthritis. What were the key steps in 75 years of glucocorticoid history until they occupied their present therapeutic position?

Update of EULAR recommendations for the treatment of Systemic Sclerosis

Professor Francesco Del Galdo share his thoughts about EULAR Recommendations for the treatment of Systemic Sclerosis.

Promising directions in the treatment of Psoriatic Arthritis

Professor Rik Lories on the current challenges in prevention and treatment of psoriatic arthritis.

Interstitial Lung Disease: from diagnosis to management

Professor Anna-Maria Hoffmann-Vold gave us a review of the most recent data from the diagnosis to the management of interstitial lung disease in RMDs.

What is New : Osteoporosis in Rheumatology

Professor Willem Lems share his thoughts on the latest developments in the diagnosis and therapy of osteoporosis as it pertains to the RMDs.

Effectiveness of Canakinumab for first line steroid free treatment in systemic juvenile idiopathic arthritis - report from EULAR2024

Professor Gerd Horneff explains the results of a  late breaking abstract from EULAR 2024, effectiveness of canakinumab for first line steroid free treatment in systemic onset juvenile idiopathic arthritis/ juvenile Still’s disease.

Early and maintained comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients

Professor Dennis McGonagle explains the results of an EULAR 2024 late breaking abstract, the PRO-SPIRIT study, early (3-month) and maintained (12-month) comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients.

Fatigue, Pain and Opioids in Rheumatological Diseases

Professor Rene Westhovens chaired an interesting session during EULAR 2024, where participants learned to recognise the range of pain and fatigue manifestations and impact in Rheumatic and Musculoskeletal Diseases and heared about options for managing different pain mechanisms in RMDs. State of the art and risks of opioid use are discussed and the role of self-management approaches to manage pain and fatigue and reduce opioid use are presented.

Cardiovascular Comorbidities of Rheumatic and Musculoskeletal Diseases

Professor Anja Strangfeld chaired an important session during EULAR 2024 on cardiovascular comorbidities of Rheumatic and Musculoskeletal Diseases and their management.

Update on EULAR/ACR Project: Risk Stratification in patients with arthralgia suspicious for progression to RA

Professor Annette H. M. van der Helm van Mil share her thoughts about EULAR Recommendations on risk stratification in patients with arthralgia suspicious for progression to Rheumatoid Arthritis.

Difficult Questions in Osteoporosis

Professor Roland Chapurlat shares his experiences on high risk osteoporosis combination terapies, on OP and CKD, as well on pregnancy and OP.

Secukinumab versus standard-of-care in axial spondyloarthritis

Professor Denis Poddubnyy shared the results of AScalate trial, Secukinumab versus standard-of-care in axial spondyloarthritis, a randomized controlled open-label trial for treat-to-target outcomes.

Lupus: what's on the horizon?

Professor David Isenberg shares an update on novel treatments for lupus and their clinical applications.

Metabolic Reprogramming in Autoimmunity

Professor Valentina Pucino chaired an interesting session during EULAR 2024 on critical metabolic pathways and the interplay between metabolism and immune responses.

Rheumatoid Arthritis Prevention: what have we learnt, and where do we go next?

Professor Raphael Micheroli chaired an exciting session during EULAR 2024, an update on the results of RA prevention trials to date, describe the lessons learnt from these RCTs.

"Asymptomatic" Hyperuricemia: Innocent bystander or menacing foe?

Professor Francisca Sivera chaired an informative session during EULAR 2024, on the long-term consequences of asymptomatic urate deposition in the joint, critically appraise the evidence regarding urate-lowering therapy for renal disease and discern the extent to which hyperuricemia contributes to cardiovascular disease.